Evgen Pharma to supply lead asset SXP-01 in autism clinical trial
Anita Riotta
Company News- 3 min read
13:13, 5th September 2019

Evgen Pharma (EVG) FOLLOW has announced an MoU to supply its lead compound SFX-01 towards a clinical trial in patients diagnosed with Autism Spectrum Disorder (ASD). The trial is sponsored by Guy's and St Thomas' NHS Foundation Trust and will be conducted at the Evelina London Children’s Hospital.

Once Evgen has supplied the drug, the Trust will lead the process to secure grant funds and gain clinical trial approval. At the end of the trial, Evgen has retained the option to acquire the clinical data spur any subsequent development and commercialisation.

The trial’s aim is to provide clarity over whether the components of SFX-01 could be geared for treating ASD. 

SFX-01 contains a “stabilised synthetic sulforaphane molecule,” a variant of which has shown to have “potential” in the treatment of ASD in a few small clinical trials in the US.

Currently, there are no approved medicines for treating thee three core symptoms of autism, “communication difficulties, social challenges and repetitive behaviour.”

Should the SFX-01 compound prove to be useful in the treatment of ASD, it would be a significant breakthrough for the disorder and disrupt a £3bn ASD market typically focused on drugs such as antidepressants meant to treat non-core symptoms. 

For more news and updates on Evgen Pharma: FOLLOW


Disclaimer & Declaration of Interest

The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.

Login or register to post comments

Recent Articles